Calmark signs distributor agreement with MTTS for Vietnam, Cambodia and Laos
Calmark Sweden AB (publ) has today entered an exclusive distributor agreement with the company MTTS Co., Ltd regarding marketing and sales of Calmark's Neo products in the countries Vietnam, Cambodia and Laos. Through this agreement, Calmark expands its launch in Asia, where there is an extensive need for safe and effective diagnostics.
MTTS was established in 2004 with the goal of delivering innovative, cost-effective solutions for newborns in need of intensive medical care. The company offers a comprehensive suite of technologies for neonatal care - from CPAP machines that treat respiratory distress syndrome to phototherapy machines that treat neonatal jaundice. These devices help healthcare professionals to deliver a better quality of healthcare to a growing number of patients, and at a lower cost.
"It feels very good to launch our product in Southeast Asia where there is a great need to simplify diagnostics for newborns," says Magdalena Tharaldsen, Director International Business Development for Calmark. "MTTS provides equipment for light treatment, which complements our diagnostic instrument, ie they have the right customer segment and are already experts in neonatal jaundice.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-06-2022 12:54 CET.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags:
